Portfolio company
Synklino ApS
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
The company develops an immunotoxin to eradicate cytomegalovirus infections for transplant patients and donor organs.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Simplexia
This company develops a vaccine against herpes simplex virus type 2 for patients with genital herpes infections.
Prophylix Pharma AS
The company develops antibody-based prophylactic treatments for fetal and neonatal alloimmune thrombocytopenia to prevent life-threatening bleeding and brain injury in newborns.
Attgeno
This company develops nitric oxide-donating drugs to treat patients with acute pulmonary hypertension and other conditions requiring targeted organ delivery.
Synerkine Pharma
This company develops fusion protein therapeutics to treat chronic pain and peripheral neuropathy for patients with inflammatory and neurodegenerative conditions.
Synthekine
This company develops engineered cytokine therapeutics and protein engineering platforms for patients with cancer and autoimmune or inflammatory diseases.
SynsoryBio
SynsoryBio develops protein therapeutics designed to sense specific disease markers and activate only at targeted tissues to treat cancer and autoimmune disorders.
Cytovation AS
This company develops peptide-based immunotherapy treatments for patients with solid tumours and cancers driven by the Wnt/β-catenin signalling pathway.
SEITO Biologics AG
This biotechnology company develops selective regulatory T cell engagers to treat patients suffering from autoimmune diseases, chronic inflammation and organ transplant rejection.